Human VSIG8 Protein, Fc tag
分子别名（Synonym）
VSIG8,C1orf204
表达区间及表达系统（Source）
Human VSIG8, Fc Tag (VS8-H5250) is expressed from human 293 cells (HEK293). It contains AA Val 22 - Gly 263 (Accession # NP_001013683.1).
Predicted N-terminus: Val 22
蛋白结构（Molecular Characterization）
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 53.7 kDa. As a result of glycosylation, the protein migrates as 55-65 kDa under reducing (R) condition, and 110-130 kDa under non-reducing (NR) condition (SDS-PAGE).
内毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
纯度（Purity）
>95% as determined by SDS-PAGE.
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景（Background）
V-set和含免疫球蛋白结构域8（VSIG8），也称为C1orf204，是Ig超家族B7家族的I型跨膜蛋白。VSIG8是从人发干的蛋白质组学分析中鉴定出来的。它在毛囊和毛囊、指甲基质的表层和口腔上皮的表层表达。
关键字： VSIG8;VSIG8蛋白;VSIG8重组蛋白;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group（股票代码：301080）是成立于2010年的跨国生物科技公司，是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球，横跨亚洲、北美洲、欧洲，在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家，与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。